IL-6 Signaling Pathway in Neurodegeneration

Overview

Interleukin-6 (IL-6) is a pleiotropic cytokine with critical roles in immune regulation, inflammation, and neuronal survival. Dysregulated IL-6 signaling is strongly implicated in the pathogenesis of Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). This pathway page examines IL-6 family cytokines, their receptors, downstream signaling cascades, and therapeutic targeting strategies for neurodegenerative diseases. ^{1Autoimmune Neuroinflammatory Diseases: Role of Interleukins2023 · PMID 37175665Open reference}

IL-6 Family Cytokines

The IL-6 family includes several cytokines that signal through gp130-containing receptor complexes: ^{2Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological alpha-synuclein2022 · PMID 35172141Open reference}

| Cytokine | Primary Sources | Key Functions | ^{3Therapy of autoimmune inflammation in sporadic amyotrophic lateral sclerosis2023 · PMID 37436778Open reference} |----------|----------------|---------------| ^{4IL-6 trans-signaling in the nervous system: implications for neurological disorders2022 · PMID 35841253Open reference} | IL-6 | Microglia, astrocytes, neurons, T cells | Acute phase response, B cell differentiation | ^{5Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology2022 · PMID 35130907Open reference} | IL-11 | Bone marrow stromal cells | Thrombopoiesis, anti-inflammatory | ^{6JAK-STAT signaling in neuroinflammation: role in neurodegenerative diseases2022 · PMID 36461606Open reference} | LIF (Leukemia Inhibitory Factor) | Astrocytes, neurons | Neuronal survival, stem cell maintenance | ^{7H3K18 lactylation of senescent microglia potentiates brain aging and Alzheimer's disease through the NFkappaB signaling pathway2023 · PMID 37697347Open reference} | OSM (Oncostatin M) | Macrophages, microglia | Inflammatory responses, tissue remodeling | ^{8Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation2022 · PMID 34267346Open reference} | CNTF (Ciliary Neurotrophic Factor) | Astrocytes | Motor neuron survival, myelin maintenance | ^{9Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial2023 · PMID 37679434Open reference} | CT-1 (Cardiotrophin-1) | Cardiomyocytes, neurons | Neurotrophic, cardioprotective | ^{10The Neuroprotection of Verbascoside in Alzheimer's Disease Mediated through Mitigation of Neuroinflammation via Blocking NF-kappaB-p65 Signaling2022 · PMID 35406030Open reference} | IL-27 | Dendritic cells, macrophages | Immunomodulatory |

Receptor Complexes

IL-6 Receptor System

IL-6 signaling is mediated through two distinct receptor systems:

Classical Signaling:

• IL-6 binds to membrane-bound IL-6Rα (CD126)

• This complex recruits gp130 (CD130) signal-transducing subunit

• Activates downstream JAK-STAT, MAPK, and PI3K/Akt pathways

Trans-Signaling:

• IL-6 binds to soluble IL-6Rα (sIL-6R)

• This complex can bind gp130 on cells lacking membrane IL-6R

• Expanded target cell population including neurons and oligodendrocytes

• Pro-inflammatory and pathologically relevant in neurodegeneration

gp130 Family Receptors

Downstream Signaling Pathways

flowchart TD
    A["IL-6"]  -->  B{"IL-6R Type"}
    B  -->|"Classical"| C["Membrane IL-6Ralpha"]
    B  -->|"Trans-signaling"| D["Soluble IL-6Ralpha"]
    C  -->  E["gp130Dimerization"]
    D  -->  E
    E  -->  F["JAK1/JAK2/TYK2"]
    F  -->  G["STAT3 Phosphorylation"]
    F  -->  H["Ras/MAPK Cascade"]
    F  -->  I["PI3K/Akt Pathway"]

    G  -->  J["STAT3 Dimerization"]
    J  -->  K["Nuclear Translocation"]
    K  -->  L["Gene Transcription"]

    H  -->  M["ERK1/2 Activation"]
    M  -->  N["Cell Proliferation<br/>Differentiation"]

    I  -->  O["Akt Activation"]
    O  -->  P["Cell Survival<br/>Anti-apoptotic"]

    L  -->  Q["Acute Phase Proteins<br/>Bcl-2, Bcl-xL<br/>MMPs, Cytokines"]
    P  -->  Q

    subgraph N["eurodegenerative Context"]
    Q  -->  R["Neuroinflammation<br/>Neuronal Death<br/>Gliosis"]
    end

JAK-STAT3 Pathway

The primary signaling cascade in IL-6 responses:

1. JAK Activation: JAK1, JAK2, and TYK2 associated with gp130 cytoplasmic domain

2. STAT3 Phosphorylation: JAKs phosphorylate STAT3 on Tyr705

3. STAT3 Dimerization: Phosphorylated STAT3 forms hom. Nuclear Transodimers 4location: STAT3 dimers translocate to nucleus

4. Gene Transcription: Activates transcription of:

   • Acute phase proteins (CRP, serum amyloid A)

   • Anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1)

   • MMPs and other cytokines

   • SOCS3 (negative feedback)

MAPK/ERK Pathway

IL-6 also activates the Ras-Raf-MEK-ERK cascade:

• Grb2/SOS recruitment to phosphorylated gp130

• Ras activation → Raf → MEK → ERK1/2

• Controls cell proliferation, differentiation, and survival

PI3K/Akt Pathway

Phosphatidylinositol 3-kinase pathway:

• PI3K recruitment to phosphorylated gp130

• Akt/PKB activation

• mTOR, GSK-3β, and FOXO transcription factor regulation

• Anti-apoptotic and pro-survival effects

Negative Regulation

SOCS3 (Suppressor of Cytokine Signaling 3)

• Induced by STAT3 as feedback inhibitor

• Binds to JAKs and gp130 to block signaling

• Critical for limiting inflammatory responses

Protein Tyrosine Phosphatases

• SHP-1: Dephosphorylates JAKs and STAT3

• PTP1B: Dephosphorylates insulin receptor and JAKs

gp130 Shedding

• Metalloproteinases cleave gp130

• Generates soluble gp130 (sgp130)

• sgp130 can neutralize IL-6 trans-signaling

Role in Alzheimer’s Disease

Elevated IL-6 in AD Brain

• Increased IL-6 in hippocampus, cortex, and cerebrospinal fluid

• Correlates with disease severity and neurofibrillary tangle burden

• Microglia and astrocytes are primary cellular sources

Mechanisms of Neurotoxicity

1. Chronic Neuroinflammation: IL-6 promotes microglial activation

2. Amyloid-β Interaction: Aβ enhances IL-6 production

3. Tau Pathology: IL-6 promotes tau phosphorylation via STAT3

4. Synaptic Dysfunction: Impairs LTP and synaptic plasticity

5. Blood-Brain Barrier: Increases BBB permeability

Neuroprotective Aspects

• Acute IL-6 can be neurotrophic

• Promotes neurogenesis in subventricular zone

• May have neuroprotective effects in early disease stages

Role in Parkinson’s Disease

IL-6 in PD Pathogenesis

• Elevated CSF and serum IL-6 in PD patients

• Associated with disease progression

• SNc dopaminergic neurons show increased IL-6R

Mechanisms

1. Dopaminergic Neuron Vulnerability: IL-6 sensitizes neurons to toxicity

2. Microglial Activation: Chronic activation contributes to neurodegeneration

3. α-Synuclein Interaction: IL-6 may enhance α-syn aggregation

4. Mitochondrial Dysfunction: Impairs complex I activity

Role in ALS

IL-6 in ALS

• Elevated IL-6 in ALS patients (CSF, serum, spinal cord)

• Correlates with disease progression rate

• Motor neurons express IL-6R and gp130

Pathogenic Mechanisms

1. Motor Neuron Toxicity: Direct pro-inflammatory effects

2. Glial Activation: Astrocyte and microglia-mediated inflammation

3. Excitotoxicity: Modulates glutamate receptor expression

4. Protein Aggregation: May affect TDP-43 pathology

Role in Multiple Sclerosis

IL-6 in MS

• Critical for Th17 cell differentiation

• Elevated in MS lesions and CSF

• Associated with disease relapse

Mechanisms

1. Autoimmunity: Th17-mediated demyelination

2. Blood-Brain Barrier: Increases endothelial permeability

3. Oligodendrocyte Death: Direct toxicity

4. Remyelination Failure: Inhibits oligodendrocyte precursor differentiation

Therapeutic Targeting

IL-6 Receptor Antibodies

JAK Inhibitors

STAT3 Inhibitors

• Direct STAT3 inhibitors in development

• Preclinical promise but toxicity concerns

Natural Compounds

• Curcumin: Modulates IL-6 signaling

• Resveratrol: Reduces IL-6 expression

• Omega-3 fatty acids: Anti-inflammatory effects

Biomarker Potential

IL-6 as Biomarker

• CSF IL-6: Elevated in AD, PD, ALS, MS

• Serum IL-6: Correlates with disease progression

• Longitudinal Tracking: May predict progression rate

Therapeutic Response

• IL-6 levels may predict anti-IL-6 therapy response

• Monitored in clinical trials

Research Directions

1. IL-6 vs. IL-6R Targeting: Understanding differential effects

2. Trans-signaling Specificity: Developing selective inhibitors

3. Cell-Type Specific Effects: Targeting microglia vs. neurons

4. Biomarker Development: IL-6 as disease marker

5. Combination Therapies: IL-6 inhibition with other approaches

See Also

• Neuroinflammation Pathway

• TNF Signaling Pathway

• JAK-STAT Signaling

• Microglia in Neurodegeneration

• Cytokine Networks

• Alzheimer’s Disease Mechanisms

• Parkinson’s Disease Mechanisms

• ALS Mechanisms